Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
- Citation:
- Leuk Lymphoma vol 54 (12) 2654-9
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Comprehensive
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 460
- Children:
- None
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- J. A. Jones A. S. Ruppert W. Zhao T. S. Lin K. Rai B. Peterson R. A. Larson G. Marcucci N. A. Heerema J. C. Byrd
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-19901, CALGB-10101
- Phases:
- 2
- Keywords: